Minervax

company

About

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

Details

Last Funding Type
Series C
Last Funding Money Raised
€22M
Industries
Biotechnology,Health Care,Life Science,Medical,Wellness
Founded date
Jan 1, 2010
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
Minervax ApS

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
12
€135.90M kr22.50M
Minervax has raised a total of €135.90M kr22.50M in funding over 2 rounds. Their latest funding was raised on Dec 15, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 15, 2022 Series C €22M 9 Pureos Bioventures
Trill Impact
Detail
Dec 15, 2022 Debt Financing €50M 1 European Investment Bank Detail
Dec 15, 2020 Series B €47.40M 7 Wellington Partners Detail
Sep 8, 2020 Series Unknown 1 Detail
Jan 21, 2019 Grant €4.40M 3 Novo Holdings
Repair Impact Fund
Detail

Investors

Number of Lead Investors
Number of Investors
8
16
Minervax is funded by 16 investors. Pureos Bioventures and Trill Impact are the most recent investors.
Investor Name Lead Investor Funding Round
Pureos Bioventures Yes Series C
Trill Impact Yes Series C
European Investment Bank Yes Debt Financing
Novo Holdings Yes Grant
Adjuvant Capital Series C
Industrifonden Series C
LF Investment Series C
Repair Impact Fund Series C
Sanofi Ventures Series C
Sunstone Life Science Ventures Series C

Employee Profiles

Number of Employee Profiles
12
Minervax has 12 current employee profiles, including Executive Per Fischer
Executive
Board member
Board member
Employee